Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats

British Journal of Pharmacology

Volumn 162, Issue 6, 2011, Pages 1389-1400

  Kuno, Yoshihiro ^a   Iyoda, Masayuki ^a   Shibata, Takanori ^a   Hirai, Yuki ^a   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

cGMP; diabetic nephropathy; matrix metalloproteinases (MMPs); nitric oxide (NO); sildenafil

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLINE; GELATINASE A; GELATINASE B; MESSENGER RNA; SILDENAFIL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; KIDNEY CORTEX; KIDNEY HYPERTROPHY; KIDNEY TUBULE CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RENAL PROTECTION; TREATMENT DURATION;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, INBRED OLETF; SULFONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79951979701     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01149.x     Document Type: Article

References (35)

1. Choi DE, Jeong JY, Lim BJ, Chung S, Chang YK, Lee SJ, et al. (2009). Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. Am J Physiol Renal Physiol 297: F362-F370.
2. Chu S, Bohlen HG, (2004). High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism. Am J Physiol Renal Physiol 287: F384-F392. (Pubitemid 39095951)
3. Craven PA, Studer RK, DeRubertis FR, (1994). Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 93: 311-320.
4. Craven PA, Studer RK, DeRubertis FR, (1995). Impaired nitric oxide release by glomeruli from diabetic rats. Metabolism 44: 695-698.
5. Dong FQ, Li H, Cai WM, Tao J, Li Q, Ruan Y, et al. (2004). Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (Engl) 117: 1040-1044. (Pubitemid 39144892)
6. Eng E, Floege J, Young BA, Couser WG, Johnson RJ, (1994). Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation? Kidney Int Suppl 45: S45-S47.
7. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. (2005). Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157. (Pubitemid 41653106)
8. Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, et al. (2006). An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 21: 2406-2416. (Pubitemid 44644511)
9. Hirashima T, Kawano K, Mori S, Matsumoto K, Natori T, (1995). A diabetogenic gene (ODB-1) assigned to the X-chromosome in OLETF rats. Diabetes Res Clin Pract 27: 91-96.
10. Hohenstein B, Daniel C, Wittmann S, Hugo C, (2008). PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transplant 23: 3427-3436.
11. Hoshiyama M, Li B, Yao J, Harada T, Morioka T, Oite T, (2003). Effect of high glucose on nitric oxide production and endothelial nitric oxide synthase protein expression in human glomerular endothelial cells. Nephron Exp Nephrol 95: e62-e68.
12. Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ, (2009). Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol 29: 274-282.
13. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD, (1997). Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 79: 958-963. (Pubitemid 28316765)
14. Johnson RJ, (1994). The glomerular response to injury: progression or resolution? Kidney Int 45: 1769-1782. (Pubitemid 24207514)
15. Kamijo H, Higuchi M, Hora K, (2006). Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Nephron Physiol 104: 12-22.
16. Kass DA, Champion HC, Beavo JA, (2007). Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101: 1084-1095. (Pubitemid 350146434)
17. Kawano K, Hirashima T, Mori S, Natori T, (1994). OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 24 (Suppl.): S317-S320.
18. Komers R, Anderson S, (2003). Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 284: F1121-F1137. (Pubitemid 36578439)
19. Komers R, Allen TJ, Cooper ME, (1994). Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes 43: 1190-1197. (Pubitemid 24361183)
20. Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, Na KR, et al. (2009). Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 257: 137-143.
21. Li B, Yang L, Shen J, Wang C, Jiang Z, (2007). The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg 105: 1034-1041; table of contents. (Pubitemid 47479318)
22. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, et al. (2002). Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45: 268-275. (Pubitemid 34208390)
23. Mankhey RW, Wells CC, Bhatti F, Maric C, (2007). 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 292: R769-R777. (Pubitemid 46207729)
24. Oruc O, Inci K, Aki FT, Zeybek D, Muftuoglu SF, Kilinc K, et al. (2010). Sildenafil attenuates renal ischemia reperfusion injury by decreasing leukocyte infiltration. Acta Histochem 112: 337-344.
25. Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM, (1997). Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 40: 910-915. (Pubitemid 27316571)
26. Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, et al. (2006). Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol 290: R435-R441.
27. Prabhakar SS, (2004). Role of nitric oxide in diabetic nephropathy. Semin Nephrol 24: 333-344. (Pubitemid 38900633)
28. Qing-Hua G, Ju-Ming L, Chang-Yu P, Zhao-Hui L, Xiao-Man Z, Yi-Ming M, (2008). The kidney expression of matrix metalloproteinase-9 in the diabetic nephropathy of Kkay mice. J Diabetes Complications 22: 408-412.
29. Reyes AA, Karl IE, Kissane J, Klahr S, (1993). L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol 4: 1039-1045.
30. Rodriguez WE, Tyagi N, Joshua IG, Passmore JC, Fleming JT, Falcone JC, et al. (2006). Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. Am J Physiol Renal Physiol 291: F694-F701. (Pubitemid 44343752)
31. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Espinoza F, Pons H, et al. (2005). Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68: 2131-2142. (Pubitemid 43117787)
32. Rosen RC, Kostis JB, (2003). Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 92: 9M-18M. (Pubitemid 37386271)
33. Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E, (2007). PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 19: 533-543. (Pubitemid 350059687)
34. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP, (1996). Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 98: 262-270. (Pubitemid 26255722)
35. Yu SM, Hung LM, Lin CC, (1997). cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95: 1269-1277.